DICE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 rugp. 2023 @ 23:00):

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas...

Stats
Šios dienos apimtis	4.33M
Vidutinė apimtis	1.75M
Rinkos kapitalizacija	2.27B
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.91
ATR14	$0.513 (1.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-09	Ra Capital Management, L.p.	Sell	786 407	Common Stock
2023-08-09	Ra Capital Management, L.p.	Sell	21 250	Stock Option (Right to Buy)
2023-08-09	Tetlow Sharon	Sell	49 841	Common Stock
2023-08-09	Tetlow Sharon	Sell	13 800	Stock Option (right to buy)
2023-08-09	Tetlow Sharon	Sell	21 250	Stock Option (right to buy)

INSIDER POWER
-56.66
Last 99 transactions
Buy: 13 025 781 \| Sell: 10 716 392

Tūris Koreliacija

Ilgas: 0.25 (neutral)

Trumpas: 0.00 (neutral)

Signal:(77.583) Neutral

DICE Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MRNS	0.883
DGNU	0.879
ABCM	0.863
ABEO	0.86
SKYW	0.86
SINO	0.859
FSFG	0.858
CGNT	0.858
DFH	0.855
IRBT	0.851

10 Labiausiai neigiamai susiję koreliacijos
WYNN	-0.869
MCFT	-0.869
LIBY	-0.867
LSCC	-0.866
ASUR	-0.865
TGLS	-0.864
ULTA	-0.863
KYCH	-0.863
ARYD	-0.863
LAKE	-0.863

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

DICE Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

-0.72
( moderate negative )

-0.74
( moderate negative )

0.36
( neutral )

-0.75
( moderate negative )

-0.13
( neutral )

0.68
( moderate )

DICE Therapeutics, Inc. Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.07

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.07

FY	2021
Pajamos:	$1.13M
Bruto pelnas:	$1.13M (100.00 %)
EPS:	$-2.11

FY	2020
Pajamos:	$863 000
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.020

Financial Reports:

No articles found.

DICE Therapeutics, Inc.

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.